Pharma Pulse: Novartis Buys Avidity for $12B, and Trump Threatens 10% Tariff Hike on Canada

Oct 28, 09:30 AM

Headliner
Share
Subscribe
This episode of Pharma Pulse discusses Novartis’ $12 billion acquisition of Avidity Biosciences to expand its RNA therapeutics portfolio, and Trump’s proposed 10% tariff increase on Canadian imports that could disrupt pharma supply chains.
Share
Subscribe
Next
Pharma Pulse: FDA Expands Priority Voucher Program, as Oral Semaglutide Shows New Benefits and Cost Plus Drugs Adds Starjemza
Top episodes
Incorporating AI into Commercialization Plans
by Pharmaceutical Commerce
Overcoming Supply Chain Challenges
by Pharmaceutical Commerce
The Capabilities of a 3PL Provider
by Pharmaceutical Commerce